HomeNewsBusinessGovt’s Rs 30,000-crore special liquidity scheme for NBFCs a non-starter, three-month tenure disappoints industry

Govt’s Rs 30,000-crore special liquidity scheme for NBFCs a non-starter, three-month tenure disappoints industry

On Wednesday, the government issued the details of the special liquidity scheme for non-banking finance companies and housing finance companies following Cabinet approval.

May 20, 2020 / 18:14 IST
Story continues below Advertisement
Finance Minister Nirmala Sitharaman (File image: Reuters)
Finance Minister Nirmala Sitharaman (File image: Reuters)

The details of the Rs 30,000 crore special liquidity facility for non-banking finance companies (NBFCs) and housing finance companies (HFCs), announced by Union Finance Minister Nirmala Sitharaman as part of the Rs 20 lakh crore economic package, has shocked the industry. Under the scheme, the funds offered are only for a three-month tenure. The industry was expecting liquidity support for at least three years.

“We are completely disappointed. With a 3-month repayment period, this scheme is a non-starter. No NBFC will be able to repay money back in that short period,” said Raman Agarwal, co-chairman of Finance Industry Development Council (FIDC), a representative body of NBFCs. “Had the government consulted with NBFCs, this would not have happened,” said Agarwal.

Story continues below Advertisement

On Wednesday, the government issued the details of the Rs 30,000 crore special liquidity scheme for non-banking finance companies and housing finance companies following Cabinet approval. The scheme was first announced by the finance minister in the 2020-21 budget speech and later fast-tracked as part of the COVID-19 economic package.

According to the details put out in the public domain by the government today, the scheme will be implemented through a special purpose vehicle (SPV) set up by a large PSU bank. This SPV will issue bonds guaranteed by the government which will be purchased by the Reserve Bank of India. The money will be then used by the SPV to acquire the debt of at least investment grade of short duration (residual maturity of up to 3 months) of eligible NBFCs / HFCs, the government said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show